-
Rahm reaches separation deal with LIV in bankruptcy court
-
ATP proposes rankings system changes, extra player bonuses
-
UN chief urges nations to end 'war on nature'
-
Russell Brand was 'monster-like', alleged victim tells UK court
-
Newcastle boss Jaissle says Fernandez-Pardo just needs a goal
-
Crowded Launches Crowded MCP, Bringing Nonprofit Financial Operations Into ChatGPT and Claude
-
Infantino offers apology but 'no answers' at FIFA meeting over World Cup plan
-
Albanian PM condemns 'chaos' as violent unrest spreads
-
Don't exclude Turkey from 'Made in Europe' plan: minister to AFP
-
Italian football suffers new blow with Champions League misery
-
French duo Justice to score 'GTA VI': game maker
-
Trump scraps plan to livestream execution after broad backlash
-
El Nino a 'terrifying' threat to coral reefs: UN biodiversity expert
-
Seven missing off Romania after latest Black Sea drone attacks
-
Barcola must get used to Liverpool highs and lows, says Iraola
-
ARKBRIDGE Outlines Jonathan Morelli’s “Picks and Shovels” AI Infrastructure Investment Strategy
-
Versus Trade Wins Best ECN/STP Broker APAC 2026, Marking Third UF Awards Recognition
-
Tech sell-off rolls on as hot inflation data stokes rate worries
-
Three dead as Istanbul sees heaviest rainfall in 80 years
-
McIlroy makes 'solid' start in rain-hit Delhi as Norgaard leads
-
US producer prices see biggest jump since 2022 in added challenge to Trump
-
Seven missing after fire on vessel in Black Sea off Romania
-
Swiatek avoids seed exodus to breeze into Wuhan last eight
-
'Severe drought' declared in parts of UK
-
PM condemns 'chaos' as violent protests grip Albania
-
IUX Announces New Web Client Portal Built for Enhanced Browser-Based Trading
-
'I couldn't breathe', Russell Brand's alleged rape victim says
-
School roof collapse kills teacher, 32 children in NW Pakistan
-
Pope's cancer operation already reshaping papacy
-
Inter skipper Martinez facing month out with thigh injury
-
Zverev cruises past De Minaur to reach Shanghai semi-finals
-
Spanish prosecutors back abuse probe into Julio Iglesias
-
Ukraine's Zelensky defies Trump with Russian refinery strikes
-
Tech sell-off deepens as US inflation sparks AI jitters
-
Holders Australia edge New Zealand 24-22 to open Rugby league World Cup
-
Southgate does not forsee a return to management
-
'Ocarina of Time': Nintendo gives Zelda classic a modern makeover
-
Two dead as Istanbul endures heaviest rainfall in 80 years
-
France charges teen shooter citing revenge for bullying in school
-
After latest Nepal flood, survivors fear for future
-
Martinez blames 'anger' for dig at Man Utd hierarchy
-
EU leaders clash over budget as spectre of French elections looms
-
Crowds build as Albanian PM tours protest aftermath
-
'No place to breathe': life in Indonesia's fire epicentre
-
China-North Korea bridge opens, 12 years late
-
'Can't sleep': Spain's housing crunch upends lives
-
Asian Cup in Saudi Arabia could be postponed but 'no hurry' to decide: AFC
-
Musk calls on Ukraine's Zelensky to 'go' after satellite slowdown row
-
Conrad wields axe after South Africa loss to Australia
-
Still smiling at 117, Albanian may be world's oldest woman
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
H.Darwish--SF-PST